BASEL, Switzerland ( TheStreet) - Novartis ( NVS), the Swiss drugmaker, said second-quarter earnings rose 19% as sales rose for many of its new product launches. Novartis said earnings were $2.44 billion vs. $2.04 billion a year earlier. Sales increased 11% to $11.72 billion. The company said recently launched products generated sales of $2.4 billion, 21% of total sales. Novartis' pharmaceuticals division saw sales rise 8% to $7.67 billion; about one-third coming of the sales came from two drugs: hypertension medicine Diovan and cancer drug Glivec -- known as Gleevec in the U.S. Novartis said sales at its vaccines and diagnostic divisions more than doubled to $564 million, though this was boosted by now completed swine flu programs in Japan and the United States. Meanwhile, Novartis said it expects to clear antitrust hurdles in its acquisition of eye-care company Alcon ( ACL) during the third or fourth quarter. Novartis also raised its sales guidance for the full year. It expects to deliver constant currency group sales growth at mid- to high-single-digits, excluding Alcon. -- Reported by Joseph Woelfel in New York. Get more stock ideas and investing advice on our sister site, Stockpickr.com.